Document:

Exhibit 4.3

 

NEITHER THIS WARRANT NOR THE SHARES OF COMMON
STOCK ISSUABLE ON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OR ANY OTHER SECURITIES LAWS (THE “ACTS”).
NEITHER THIS WARRANT NOR THE SHARES OF COMMON STOCK PURCHASABLE HEREUNDER MAY BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN
THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS WARRANT OR COMMON STOCK PURCHASABLE HEREUNDER, AS APPLICABLE, UNDER
THE ACTS, OR (B) AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION THAT REGISTRATION IS NOT REQUIRED UNDER SUCH
ACTS.

  

XRPRO SCIENCES, INC.

WARRANT AGREEMENT

 

VOID AFTER 5:00 P.M. NEW YORK TIME, APRIL 29,
2020

 

Warrant No.:              

 

Number of Shares of Common Stock: 

 

Date of Exchange: January 31, 2015 (“Exchange
Date”)

 

Date of Issuance:  April 30, 2013 (“Issuance
Date”)

  

1.Basic Terms.
This Warrant Agreement (the “Warrant”) certifies that, for value received, the registered holder specified below
or its registered assigns (“Holder”) is entitled to purchase from XRpro Sciences, Inc., formerly known as Caldera
Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at One Kendall Square, Cambridge, Massachusetts
02139 (the “Corporation”), subject to adjustments as provided herein, [____________] ([________]) shares of
the Common Stock, $.001 par value, of the Corporation (the “Common Stock”) at the price per share shown below
(the “Exercise Price”).

  

Holder:

  

Exercise Price per share:$1.925

 

Except as specifically provided
otherwise, all references in this Warrant to the Exercise Price and the number of shares of Common Stock purchasable hereunder
shall be to the Exercise Price and number of shares after any adjustments are made thereto pursuant to this Warrant.

 

This Warrant is issued pursuant
to an Exchange Agreement dated as of January 31, 2015 by and between the Holder and the Corporation in exchange for the warrant
issued to the Holder by the Corporation on April 30, 2013 (the “Agreement”).

 

2.Corporation’s
Representations/Covenants. The Corporation represents and covenants that the shares of Common Stock issuable upon the exercise
of this Warrant shall at delivery be fully paid and non-assessable and free from taxes, liens, encumbrances and charges with respect
to their purchase. The Corporation shall take any necessary actions to assure that the par value per share of the Common Stock
is at all times equal to or less than the then current Exercise Price per share of Common Stock issuable pursuant to this Warrant.
The Corporation shall at all times reserve and hold available sufficient shares of Common Stock to satisfy all conversion and purchase
rights of outstanding convertible securities, options and warrants of the Corporation, including this Warrant.

 

    	 

    	 

    

 

3.Method of Exercise;
Fractional Shares.

 

(a)This Warrant is exercisable
at the option of the Holder at any time by surrendering this Warrant, on any business day during the period (the “Exercise
Period”) beginning the business day after the issue date of this Warrant specified above and ending at 5:00 p.m. (New
York time) five (5) years after the issue date. To exercise this Warrant, the Holder shall deliver to the Corporation (whether
via facsimile or otherwise) the executed exercise form (the “Exercise Notice”) (substantially in the form of
that attached hereto) and, unless this Warrant is being exercised on a cashless basis as set forth in Section 3(b) below, together
with payment for the Common Stock purchased under this Warrant. The Holder shall not be required to deliver the original of this
Warrant in order to effect an exercise hereunder. The principal office of the Corporation is located at the address specified in
Section 1 of this Warrant; provided, however, that the Corporation may change its principal office upon notice to the Holder. Payment
shall be made by check payable to the order of the Corporation or by wire transfer. This Warrant is not exercisable with respect
to a fraction of a share of Common Stock. In lieu of issuing a fraction of a share remaining after exercise of this Warrant as
to all full shares covered by this Warrant, the Corporation shall either at its option: (i) pay to the Holder an amount in cash
equal to the product of (x) such fraction, multiplied by (y) the Fair Market Value (as defined below) of one share of Common Stock
on the date of exercise; or (ii) issue scrip for the fraction in registered or bearer form which shall entitle the Holder to receive
a certificate for a full share of Common Stock on surrender of scrip aggregating a full share.

 

(b)In lieu of exercising
this Warrant for cash pursuant to Section 3(a), the Holder may elect to exercise this Warrant on a cashless basis by surrender
of this Warrant at the principal office of the Corporation together with notice of such election, in which event the Corporation
shall issue to the Holder a number of shares of Common Stock computed using the following formula:

 

	 		Y
    (A - B)	 
	 	X
    =	       A	 

 

Where:

 

X --The number of shares
of Common Stock to be issued to the Holder under this Section 3(b).

 

Y --The number of shares
of Common Stock for which under this Warrant is being exercised pursuant to this Section 3(b) (at the date of such calculation).

 

A --The Fair Market
Value (as defined below) of a share of Common Stock on the immediately preceding Trading Day (as defined below).

 

B --The Exercise Price
(as adjusted to the date of such calculations).

 

    	2

    	 

    

 

For purposes of this Section
3(b), the “Fair Market Value” of a share of Common Stock shall mean (i) the volume weighted average of the closing
sales prices of the Common Stock for such day on all domestic securities exchanges on which the Common Stock may at the time be
listed; (ii) if there have been no sales of the Common Stock on any such exchange on any such day, the average of the highest bid
and lowest asked prices for the Common Stock on all such exchanges at the end of such day; (iii) if on any such day the Common
Stock is not listed on a domestic securities exchange, the closing sales price of the Common Stock as quoted on the OTC Bulletin
Board, OTCQX or OTCQB (or any successors to any of the foregoing) or similar quotation system or association for such day; or (iv)
if there have been no sales of the Common Stock on the OTC Bulletin Board, OTCQX or OTCQB (or any successors to any of the foregoing)
or similar quotation system or association on such day, the average of the highest bid and lowest asked prices for the Common Stock
quoted on the OTC Bulletin Board, OTCQX or OTCQB (or any successors to any of the foregoing) or similar quotation system or association
at the end of such day; in each case, averaged over ten (10) consecutive Trading Days ending on the Trading Day immediately prior
to the day as of which “Fair Market Value” is being determined. If at any time the Common Stock is not listed on any
domestic securities exchange or quoted on the OTC Bulletin Board, OTCQX or OTCQB (or any successors to any of the foregoing) or
similar quotation system or association, the “Fair Market Value” of the Common Stock shall be the fair market value
per share as determined in good faith by the Board of Directors of the Corporation. “Trading Day” means a day on which
the principal securities exchange or securities market on which the Common Stock is principally traded is open for business.

 

(c)On or before the
third (3rd) Trading Day (as defined below) following the later of (i) the date on which the Corporation has received an Exercise
Notice or (ii) the date on which the Corporation receives payment of the Exercise Price (which shall not apply for cashless exercises),
the Corporation shall transmit an acknowledgment of confirmation of receipt of such Exercise Notice to the Holder and the Corporation’s
transfer agent (the “Transfer Agent”). On or before the fifth (5th) Trading Day following the later of (i) the
date on which the Corporation has received such Exercise Notice or (ii) the date on which the Corporation receives the Exercise
Price (such later date, the “Delivery Date”), the Corporation shall (x) provided that the Transfer Agent is
participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, upon the request
of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise
to the Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system, or (y)
if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver to the Holder
or, at the Holder’s instruction pursuant to the Exercise Notice, the Holder’s agent or designee, in each case, sent
by reputable overnight courier to the address as specified in the applicable Exercise Notice, a certificate, registered in the
Corporation’s share register in the name of the Holder or its designee (as indicated in the applicable Exercise Notice),
for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. Upon the later of (i) the date
on which the Corporation has received the Exercise Notice or (ii) the date on which the Corporation receives the Exercise Price,
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to
which this Warrant has been exercised, irrespective of the date such shares of Common Stock are credited to the Holder’s
DTC account or the date of delivery of the certificates evidencing such shares of Common Stock (as the case may be).

 

    	3

    	 

    

 

(d)If the Corporation
fails to deliver to the Holder a certificate or certificates representing the shares of Common Stock issuable upon exercise of
this Warrant pursuant to an exercise by the close of business on the fifth (5th) Trading Day after the date on which the Corporation
has received an Exercise Notice or the date on which the Corporation receives payment of the Exercise Price, and if after such
fifth (5th) Trading Day the Holder is required by its broker to purchase (in an open market transaction or otherwise) shares of
Common Stock to deliver in satisfaction of a sale by the Holder of the shares of Common Stock issuable upon exercise of this Warrant
which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Corporation shall (i) pay in
cash to the Holder the amount by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for
the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the number of shares of Common Stock
issuable upon exercise of this Warrant that the Corporation was required to deliver to the Holder in connection with the exercise
at issue times (B) the price at which the sell order giving rise to such purchase obligation was executed, and (ii) at the option
of the Holder, either reinstate the portion of the Warrant and equivalent number of shares of Common Stock issuable upon exercise
of this Warrant for which such exercise was not honored or deliver to the Holder the number of shares of Common Stock that would
have been issued had the Corporation timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise
of shares of Common Stock issuable upon exercise of this Warrant with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (i) of the immediately preceding sentence the Corporation shall be required to pay the Holder $1,000.
The Corporation’s obligations under this Section 3(d) will be subject to the Holder providing the Corporation written notice
indicating the amounts payable to the Holder in respect of the Buy-In, together with applicable confirmations and other evidence
reasonably requested by the Corporation. Nothing herein shall limit a Holder’s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with
respect to the Corporation’s failure to timely deliver certificates representing Common Stock upon exercise of this Warrant
as required pursuant to the terms hereof.

 

4.Protection Against
Dilution. If the Corporation, with respect to the Common Stock, (a) pays a dividend or makes a distribution on shares of common
stock that is paid in shares of common stock or in securities convertible into or exchangeable for Common Stock (in which latter
event the number of shares of common stock initially issuable upon the conversion or exchange of such securities shall be deemed
to have been distributed), (b) subdivides outstanding shares of Common Stock into a greater number of shares, (c) combines outstanding
shares of Common Stock into a smaller number of shares, or (d) issues by reclassification of Common Stock any shares of capital
stock of the Corporation, the Exercise Price and number of shares purchasable under this Warrant in effect immediately prior thereto
shall be adjusted so that each Holder thereafter shall be entitled to receive the number and kind of shares of Common Stock or
other capital stock of the Corporation that it would have owned or been entitled to receive in respect of this Warrant immediately
after the happening of any of the events described above had this Warrant been converted immediately prior to the happening of
that event. An adjustment made in accordance with this section shall become effective immediately after the record date, in the
case of a dividend, and shall become effective immediately after the effective date, in the case of a subdivision, combination,
or reclassification. If, as a result of an adjustment made in accordance with this Section 4, the Holder becomes entitled to receive
shares of two or more classes of capital stock or shares of Common Stock and other capital stock of the Corporation, the board
of directors (whose determination shall be conclusive) shall determine the allocation of the adjusted Exercise Price and number
of shares purchasable under this Warrant between or among shares of such classes of capital stock or shares of Common Stock and
other capital stock.

 

    	4

    	 

    

 

5.Adjustment for
Reorganization, Consolidation, Merger. In the event of any (a) consolidation or merger to which the Corporation is a party
other than a consolidation or merger in which the Corporation is the continuing corporation, (b) the sale or conveyance to another
person or entity of the property of the Corporation as an entirety or substantially as an entirety, (c) any statutory exchange
of securities with another person or entity (including any exchange effected in connection with a merger of a third corporation
into the Corporation), (d) capital reorganization of the Corporation, (e) reclassification of the stock of the Corporation, or
(f) or other similar transaction (each such transaction referred to herein as “Reorganization”), this Warrant
shall remain outstanding and shall thereafter, in lieu of or in addition to (as the case may be) the number of shares of Common
Stock then purchasable under this Warrant, the Holder shall thereupon be entitled to receive and provision shall be made therefor
in any agreement relating to a Reorganization, the kind and number of securities or property (including cash) of the Corporation
or of the successor person or entity resulting from such Reorganization which the Holder would have owned or been entitled to receive
as a result of such Reorganization had this Warrant been exercised immediately prior to such Reorganization (and assuming the Holder
failed to make an election, if any was available, as to the kind or amount of securities, property or cash receivable by reason
of such Reorganization; provided that if the kind or amount of securities, property or cash receivable upon such Reorganization
is not the same for each share of common stock in respect of which such rights of election shall not have been exercised (“non
electing share”) then for the purpose of this section the kind and amount of securities, property or cash receivable upon
such Reorganization for each non electing share shall be deemed to be the kind and amount so receivable per share by a plurality
of the non electing shares). In any case, appropriate adjustment shall be made in the application of the provisions herein set
forth with respect to the rights and interests thereafter of the Holder, to the end that the provisions set forth herein shall
thereafter be applicable, as nearly as reasonably may be, in relation to any shares, other securities or property thereafter receivable
upon exercise of this Warrant (including, in the case of any consolidation, merger, sale or similar transaction in which the successor
or purchasing person or entity is not the Corporation, an immediate adjustment in the Exercise Price to the value per share for
the Common Stock reflected by the terms of such consolidation, merger, sale or similar transaction, and a corresponding immediate
adjustment to the number of shares of Common Stock acquirable upon exercise of this Warrant without regard to any limitations or
restrictions on exercise, if the value so reflected is less than the Exercise Price in effect immediately prior to such consolidation,
merger, sale or similar transaction). The provisions of this section similarly apply to successive Reorganizations.

 

    	5

    	 

    

 

6.Notice of Adjustment.
On the happening of an event requiring an adjustment of the Exercise Price or the shares purchasable under this Warrant, the Corporation
shall, within fifteen (15) business days, give written notice to the Holder stating the adjusted Exercise Price and the adjusted
number and kind of securities or other property purchasable under this Warrant resulting from the event and setting forth in reasonable
detail the method of calculation and the facts upon which the calculation is based.

 

7.Dissolution, Liquidation.
In case of the voluntary or involuntary dissolution, liquidation or winding up of the Corporation (other than in connection with
reorganization, consolidation, merger, or other transaction covered by paragraph 5 above) is at any time proposed; the Corporation
shall give at least thirty days prior written notice to the Holder. Such notice shall contain: (a) the date on which the transaction
is to take place; (b) the record date (which shall be at least thirty (30) days after the giving of the notice) as of which holders
of Common Stock will be entitled to receive distributions as a result of the transaction; (c) a brief description of the transaction,
(d) a brief description of the distributions to be made to holders of Common Stock as a result of the transaction; and (e) an estimate
of the fair value of the distributions. On the date of the transaction, if it actually occurs, this Warrant and all rights under
this Warrant shall terminate.

 

8.Rights of Holder.
The Corporation shall deliver to the Holder all notices and other information provided to its holders of shares of Common Stock
or other securities which may be issuable hereunder concurrently with the delivery of such information to the holders. This Warrant
does not entitle the Holder to any voting rights or, except for the foregoing notice provisions, any other rights as a shareholder
of the Corporation. No dividends are payable or will accrue on this Warrant or the shares of Common Stock purchasable under this
Warrant until, and except to the extent that, this Warrant is exercised. Upon the surrender of this Warrant and payment of the
Exercise Price as provided above, the person or entity entitled to receive the shares of Common Stock issuable upon such exercise
shall be treated for all purposes as the record holder of such shares as of the close of business on the date of the surrender
of this Warrant for exercise as provided above. Upon the exercise of this Warrant, the Holder shall have all of the rights of a
shareholder in the Corporation.

 

9.Exchange for Other
Denominations. This Warrant is exchangeable, on its surrender by the Holder to the Corporation, for a new Warrant of like tenor
and date representing in the aggregate the right to purchase the balance of the number of shares purchasable under this Warrant
in denominations and subject to restrictions on transfer contained herein, in the names designated by the Holder at the time of
surrender.

 

10.Substitution.
Upon receipt by the Corporation of evidence satisfactory (in the exercise of reasonable discretion) to it of the ownership of and
the loss, theft or destruction or mutilation of the Warrant, and (in the case or loss, theft or destruction) of indemnity satisfactory
(in the exercise of reasonable discretion) to it, and (in the case of mutilation) upon the surrender and cancellation thereof,
the Corporation will issue and deliver, in lieu thereof, a new Warrant of like tenor.

 

11.Restrictions on
Transfer. Neither this Warrant nor the shares of Common Stock issuable on exercise of this Warrant have been registered under
the Securities Act or any other securities laws (the “Acts”). Neither this Warrant nor the shares of Common
Stock purchasable hereunder may be sold, transferred, pledged or hypothecated in the absence of (a) an effective registration statement
for this Warrant or Common Stock purchasable hereunder, as applicable, under the Acts, or (b) an opinion of counsel reasonably
satisfactory to the Corporation that registration is not required under such Acts. If the Holder seeks an opinion as to transfer
without registration from Holder’s counsel, the Corporation shall provide such factual information to Holder’s counsel
as Holder’s counsel reasonably requests for the purpose of rendering such opinion. Each certificate evidencing shares of
Common Stock purchased hereunder will bear a legend describing the restrictions on transfer contained in this paragraph unless,
in the opinion of counsel reasonably acceptable to the Corporation, the shares need no longer to be subject to the transfer restrictions.

 

    	6

    	 

    

 

12.Transfer.
Subject to the transfer conditions referred to in the legend endorsed hereon, this Warrant and all rights hereunder are transferable,
in whole or in part, only on the books of the Corporation by the Holder in person or by attorney, on surrender of this Warrant,
properly endorsed. Under no circumstances may this Warrant be assigned or transferred by the Corporation.

 

13.Recognition of
Holder. Prior to due presentment for registration of transfer of this Warrant, the Corporation shall treat the Holder as the
person exclusively entitled to receive notices and otherwise to exercise rights under this Warrant. All notices required or permitted
to be given to the Holder shall be in writing and shall be given by first class mail, postage prepaid, addressed to the Holder
at the address of the Holder appearing in the records of the Corporation.

 

14.Payment of Taxes.
The Corporation shall pay all taxes and other governmental charges, other than applicable income taxes, that may be imposed with
respect to the issuance of shares of Common Stock pursuant to the exercise of this Warrant.

 

15.Headings.
The headings in this Warrant are for purposes of convenience in reference only, shall not be deemed to constitute a part of this
Warrant and shall not affect the meaning or construction of any of the provisions of this Warrant.

 

16.Miscellaneous.
This Warrant may not be changed, waived, discharged or terminated except by an instrument in writing signed by the Corporation
and the Holder. This Warrant and the rights evidenced hereby shall be binding upon and shall inure to the benefit of the parties
hereto and the successors of the Corporation and the successors and permitted assigns of the Holder. Such successors and/or assigns
of the Holder shall be deemed to be a Holder for all purposes hereunder. This Warrant, together with the Agreement, constitutes
the sole and entire agreement of the parties to this Warrant with respect to the subject matter contained herein, and supersedes
all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the
event of any inconsistency between the statements in the body of this Warrant and the Agreement, the statements in the body of
this Warrant shall control. If any term or provision of this Warrant is invalid, illegal or unenforceable in any jurisdiction,
such invalidity, illegality or unenforceability shall not affect any other term or provision of this Warrant or invalidate or render
unenforceable such term or provision in any other jurisdiction.

 

17.Governing Law.
This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to its
principles governing conflicts of law.

 

    	7

    	 

    

 

	 	XRPRO SCIENCES, INC.
	 	 	 
	 	By:	 
	 	 	Name:  Richard Cunningham
	 	 	Title: President and Chief Executive Officer

 

    	8

    	 

    

  

XRPRO SCIENCES, INC.

Form of Transfer

 

(To be executed by the Holder to transfer the
Warrant)

 

For value received the undersigned
registered holder of the attached Warrant hereby sells, assigns, and transfers the Warrant to the Assignee(s) named below:

 

	 	Names of Assignee	 	 	 	Address	 	 	Taxpayer ID No.	 	Number of Shares subject to transferred Warrant
	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 

 

The undersigned registered holder further irrevocably
appoints ___________________________________ attorney (with full power of substitution) to transfer this Warrant
as aforesaid on the books of the Corporation.

 

	 Date:                                                                               	                                                                                        
		Signature

 

    	9

    	 

    

 

XRPRO SCIENCES, INC.

Exercise Form

 

(To be executed by the Holder to purchase Common
Stock pursuant to the Warrant)

  

The undersigned holder of the attached Warrant
hereby irrevocably elects to exercise purchase rights represented by such Warrant for, and to purchase, ___________ shares of Common
Stock of XRpro Sciences, Inc., a Delaware corporation.

 

________ The undersigned tenders cash payment
for those shares.

 

 ________ The undersigned is exercising
this Warrant as a cashless exercise pursuant to Section 3(b) of the Warrant.

 

The undersigned requests that (1) a certificate
for the shares be issued in the name of the undersigned and (2) if the number of shares with respect to which the undersigned
holder has exercised purchase rights is not all of the shares purchasable under this Warrant, that a new Warrant of like tenor
for the balance of the remaining shares purchasable under this Warrant be issued.

 

	 Date:                                                                               	                                                                                        
		Signature

 

 

10Exhibit 10.1

 

EXCHANGE
AGREEMENT

 

THIS EXCHANGE AGREEMENT
(the “Agreement”) is dated as of January 31, 2015, by and between XRpro Sciences, Inc., formerly known
as Caldera Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at One Kendall Square, Boston, Massachusetts
02139 (the “Company”) and _____________________________________________________________ with a residence located
at ____________________________________________________________ (the “Securityholder”).

 

WHEREAS:

 

A. The Company is
currently offering for sale on a best efforts basis in a private placement of up to 1,265,000 Units (each Unit consisting of four
shares of the Company’s common stock, par value $.001 per share (the “Common Stock”) and a Warrant to purchase
common stock in the Company at $1.75 per share) at a price of $7.00 per Unit (the “Private Placement”) and
has agreed to issue until January 31, 2015, in addition to such 1,265,000 Units that will be offered in the Private Placement,
shares of Common Stock to certain current Securityholders of the Company in exchange for the securities of the Company currently
held by or owed as dividends to such Securityholders. In addition the Company has also offered to issue until January 31, 2015
to certain warrant holders ( including the placement agent and its designees) a new warrant in exchange for certain existing warrants
(other than the advisory warrants exercisable for $.01), which new warrants substantially similar to the existing warrant; however,
the new warrant terms will provide for a reduction in exercise price, the elimination of the anti-dilution rights for new stock
issuances at per share prices lower than the exercise price, the addition of assignment rights for the warrant holders and the
addition of certain buy-in–rights for the warrants that previously did not have buy-in rights in the event of the Company’s
failure to timely deliver the shares of Common Stock underlying the warrant.

 

B.The Securityholder
owns ________ shares of Series B Preferred Stock of the Company (the “Series B Preferred”) and desires to exchange
all of the shares of Series B Preferred owned by the Securityholder together with all accrued and unpaid dividends thereon through
the date of the exchange for _________ shares of Common Stock of the Company (which number is derived by dividing (x) the sum
of the total cash paid by the Securityholder to the Company for the Securityholder’s initial investment in the Series B
Units (comprised of Series B Preferred and a Warrant) plus the accrued and unpaid dividends on the Series B Preferred (the “Series
B Units”) by (y) $1.75;

 

C. The exchange of
the Series B Preferred together with the accrued and unpaid dividends for the Common Stock will be made in reliance upon the exemption
from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”).

 

    	 

    	 

    

 

NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants hereinafter contained, the parties hereto agree
as follows:

 

1.EXCHANGE.

 

1.1 Exchange.
Subject to the satisfaction or waiver of the conditions with respect to the Closing set forth in Sections 5 and 6 below, at the
Closing the Securityholder and the Company shall, pursuant to Section 3(a)(9) of the Securities Act, exchange _____ shares of
Series B Preferred for _____ shares of Common Stock (which number of shares of Series B Preferred is derived by dividing (x) the
sum of the total cash paid by the Securityholder to the Company for the Securityholder’s initial investment in the Series
B Preferred plus the accrued and unpaid dividends on the Series B Preferred by (y) $1.75.

 

1.2
Closing. The closing of the exchange contemplated herein (the “Closing”) shall occur at the offices
of Gracin & Marlow, LLP. The date and time of the Closing shall be 10:00 a.m., New York time, on the first Business Day on
which the conditions to the Closing set forth in Sections 5 and 6 below are satisfied or waived (or such later date as is mutually
agreed to by the Company and the Securityholder) but in no event later than January 31, 2015.

 

1.3 Consideration.
The Common Stock shall be issued to the Securityholder in exchange for the Series B Preferred without the payment of any additional
consideration.

 

1.4 Delivery.
In exchange for the shares of Series B Preferred, within five business days of receipt by the Company from the Securityholder
(or its designee) of the stock certificates evidencing the shares of Series B Preferred (or in the event or the lost, theft or
destruction of the Series B Preferred stock certificate, an affidavit with respect thereto in the form reasonably acceptable to
the Company), which shall be delivered at the Closing, the Company shall deliver or cause to be delivered to the Securityholder
the shares of Common Stock issued in exchange for shares of Series B Preferred. As of the Closing Date, the shares of Series B
Preferred exchanged for Common Stock shall be null and void and any and all rights arising thereunder shall be extinguished, including
all dividend rights.

 

2.
COMPANY REPRESENTATIONS AND WARRANTIES.

 

The
Company represents and warrants to the Securityholder that:

 

2.1Reporting
Company Status. The Company is a corporation duly organized, validly existing and in good standing under the laws of
the State of Delaware, and has the requisite corporate power to own its properties and to carry on its business as now being conducted.
The Company is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature
of the business conducted or property owned by it makes such qualification necessary other than those jurisdictions in which the
failure to so qualify would not have a material and adverse effect on the business, operations, properties, prospects or condition
(financial or otherwise) of the Company. The Company has registered its Common Stock pursuant to Section 12 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”).

 

2.2Authorized
Shares. The Company has authorized the issuance of the shares of Common Stock and, when issued the Common Stock will
be duly and validly issued, fully paid and non-assessable and will not subject the holder thereof to personal liability by reason
of being such holder.

 

2.3Exchange
Agreement. This Agreement and the transactions contemplated hereby have been duly and validly authorized by the Company,
this Agreement has been duly executed and delivered by the Company and this Agreement, when executed and delivered by the Company,
will be, a valid and binding agreement of the Company enforceable in accordance with its terms, subject as to enforceability to
general principles of equity and to bankruptcy, insolvency, moratorium, and other similar laws affecting the enforcement of creditors’
rights generally.

 

    	2

    	 

    

 

2.4Non-contravention.
The execution and delivery of this Agreement by the Company, the issuance of the Common Stock, and the consummation by the
Company of the other transactions contemplated by this Agreement do not and will not conflict with or result in a breach by the
Company of any of the terms or provisions of, or constitute a default under: (i) the certificate of incorporation or by-laws of
the Company; (ii) any indenture, mortgage, deed of trust, or other material agreement or instrument to which the Company is a
party or by which it or any of its properties or assets are bound; (iii) any existing applicable law, rule, or regulation or any
applicable decree, judgment; or (iv)any order of any court, United States federal or state regulatory body, administrative agency,
or other governmental body having jurisdiction over the Company or any of its properties or assets, except such conflict, breach
or default which would not have a material adverse effect on the transactions contemplated herein. The Company is not in violation
of any material laws, governmental orders, rules, regulations or ordinances to which its property, real, personal, mixed, tangible
or intangible, or its businesses related to such properties, are subject.

 

2.5Approvals.
No authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization, or
stock exchange or market is required to be obtained by the Company for the issuance and exchange of the Common Stock to the Securityholder
as contemplated by this Agreement, except such authorizations, approvals and consents that have been obtained.

 

2.6SEC
Documents, Financial Statements. The Company has filed on a timely basis all reports, schedules, forms, statements
and other documents required to be filed by it with the Securities and Exchange Commission (“SEC”) pursuant to the
reporting requirements of the Exchange Act, including material filed pursuant to Section 13(a) or 15(d) (the “SEC Documents”).
As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Act
or the Exchange Act as the case may be and the rules and regulations of the SEC promulgated thereunder and other federal, state
and local laws, rules and regulations applicable to such SEC Documents, and none of the SEC Documents contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. The financial statements of the Company included
in the SEC Documents comply as to form in all material respects with applicable accounting requirements and the published rules
and regulations of the SEC or other applicable rules and regulations with respect thereto. Such financial statements have been
prepared in accordance with generally accepted accounting principles applied on a consistent basis during the periods involved
(except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim
statements, to the extent they may not include footnotes or may be condensed or summary statements) and fairly present in all
material respects the financial position of the Company as of the dates thereof and the results of operations and cash flows for
the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).

 

3.
SECURITYHOLDER REPRESENTATIONS AND WARRANTIES.

 

As
a material inducement to the Company to enter into this Agreement and consummate the Exchange, the Securityholder represents,
warrants and covenants with and to the Company as follows:

 

3.1Authorization
and Binding Obligation. The Securityholder has the requisite legal capacity, power and authority to enter into, and perform
under, this Agreement and to acquire the Common Stock being issued to such Securityholder hereunder. The execution, delivery and
performance of this Agreement by such Securityholder and the consummation by such Securityholder of the transactions contemplated
hereby and thereby have been duly authorized by all requisite corporate, partnership or similar action on the part of such Securityholder
and no further consent or authorization is required. This Agreement has been duly authorized, executed and delivered. This Agreement
constitutes the legal, valid and binding obligations of the Securityholder, enforceable against the Securityholder in accordance
with their respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable
creditors' rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state
securities laws.

 

    	3

    	 

    

 

3.2
Beneficial Owner. With respect to the Series B Preferred: (i) the Securityholder owns, good and marketable title
to the Series B Preferred and the right to receive dividends thereon, free and clear of any liens or encumbrances and the Series
B Preferred has been pledged to any third party; (ii) Neither the shares of Series B Preferred held by the Securityholder nor
the right to receive dividends thereon is subject to any transfer restriction, other than the restriction that they have not been
registered under the Securities Act or applicable state securities laws and, therefore, cannot be resold unless registered under
the Securities Act or applicable state securities laws or in a transaction exempt from or not subject to the registration requirements
of the Securities Act or applicable state securities laws; (iii) the Securityholder has not entered into any agreement or understanding
with any person or entity to dispose of any of the shares of Series B Preferred or the dividends to be issued with respect to
the Series B Preferred; and (iv) at the Closing, the Securityholder will convey to the Company good and marketable title to the
Series B Preferred and the Common Stock dividends thereon, free and clear of any security interests, liens, adverse claims, encumbrances,
taxes or encumbrances.

 

3.3Liens.
There are no outstanding liens, claims, offset rights, or other encumbrances relating to the Series B Preferred. To the knowledge
of the Securityholder, the exchange by the Securityholder and the consummation of the transactions herein, does not by itself
or with the passage of time violate or infringe upon the rights of any third parties or result or could reasonably result in any
claims against the Securityholder or the Company.

 

3.4Sale or Transfer.
The Securityholder has not sold, assigned, conveyed, transferred, mortgaged, hypothecated, pledged or encumbered or otherwise
permitted any lien to be incurred with respect to the Series B Preferred.

 

3.5Proceedings.
No proceedings relating to the Series B Preferred are pending or, to the knowledge of the Securityholder, threatened before any
court, arbitrator or administrative or governmental body that would adversely affect the Securityholder’s right and ability
to surrender and exchange the Series B Preferred.

 

3.6Conveyance.
The Securityholder has full legal and equitable title to the Series B Preferred, free and clear of all liens, pledges or encumbrances
of any kind, nature or description, with full and unrestricted legal power, authority and right to enter into this Agreement and
to transfer and deliver such Series B Preferred to the Company pursuant hereto, and upon delivery of the Series B Preferred to
the Company, the Company will be the owner of the Series B free and clear of all liens, claims, pledges or encumbrances of any
kind, nature or description.

 

3.7Action.
The Securityholder has taken no action that would impair its ability to transfer the Series B Preferred.

 

3.8Interest.
No person other than the Securityholder has any right or interest in the Series B Preferred or the dividends accrued to the date
of closing.

 

    	4

    	 

    

 

3.9Tax Consequences.
The Securityholder acknowledges that the exchange of the Series B Preferred may involve tax consequences to the Securityholder
and that this Agreement does not contain tax advice. The Securityholder acknowledges that it has not relied and will not rely
upon the Company with respect to any tax consequences related to the exchange of the Series B Preferred. The Securityholder assumes
full responsibility for all such consequences and for the preparation and filing of any tax returns and elections which may or
must be filed in connection with the Series B Preferred.

 

3.10 Reliance on
Exemptions. The Securityholder understands that the shares of Common Stock being issued in the exchange are being issued in
reliance on specific exemptions from the registration requirements of United States federal and state securities laws provided
by Section 3(a)(9) and that the Company is relying in part upon the truth and accuracy of, and the Securityholder’s compliance
with, the representations, warranties, agreements, acknowledgments and understandings of the Securityholder set forth herein in
order to determine the availability of such exemptions and the eligibility of the Securityholder to acquire the Common Stock.

 

3.11 No
Governmental Review. The Securityholder understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement of the Common Stock or the fairness or suitability
of the exchange with the Common Stock nor have such authorities passed upon or endorsed the merits of the exchange of the Common
Stock.

 

3.12
No Conflicts. The execution, delivery and performance by the Securityholder of this Agreement and the consummation
by the Securityholder of the transactions contemplated hereby will not (i) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which the Securityholder is a party or (ii) result
in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable
to the Securityholder, except in the case of clause (i) or (ii) above, for such conflicts, defaults, rights or violations which
would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Securityholder
to perform its obligations hereunder.

 

3.13
No Public Sale or Distribution. The Securityholder is acquiring the Common Stock for its own account and not with a
view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable securities
laws, except pursuant to sales registered or exempted under the Securities Act. The Securityholder does not presently have any
agreement or understanding, directly or indirectly, with any person to distribute any of the shares of Common Stock for its own
account or with a view towards, or for resale in connection with, the public sale of securities in violation of applicable securities
laws.

 

3.14Information.
The Securityholder and its advisors, if any, have been furnished with all materials relating to the business, finances and operations
of the Company and materials relating to the offer and sale of the Common Stock which have been requested by the Securityholder.
The Securityholder and its advisors, if any, have been afforded the opportunity to ask questions of the Company. The Securityholder
understands that its exchange of the Common Stock involves a high degree of risk. The Securityholder has sought such accounting,
legal and tax advice as it has considered necessary to make an informed decision with respect to its acquisition of the Common
Stock. Without limiting the generality of the foregoing, the Securityholder has also had the opportunity to obtain and to review:
(i) the Company’s Private Placement Memorandum dated as of December 4, 2014, as amended by Supplement No. 1 with respect
to the offering of up to $8,855,000 Units, each Unit comprised of four shares of Common Stock and a warrant exercisable for one
share of common stock at an exercise price of $1.75, (ii) the Company’s Quarterly Reports on Form 10-Q for the quarters
ended March 31, 2014, June 30, 2014 and September 30, 2014, and (iii) the Company’s Annual Report on Form 10-K for the year
ended December 31, 2013.

 

    	5

    	 

    

 

3.15 Transfer or
Resale. The Securityholder understands that: (i) the shares of Common Stock have not been and are not being registered under
the Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently
registered thereunder; (B) the Securityholder shall have delivered to the Company (if requested by the Company) an opinion of
counsel to the Securityholder, in a form reasonably acceptable to the Company, to the effect that the shares of Common Stock to
be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration; or (C)
the Securityholder provides the Company with reasonable assurance that the shares of Common Stock can be sold, assigned or transferred
pursuant to Rule 144 or Rule 144A promulgated under the Securities Act (or a successor rule thereto) (collectively, “Rule
144”) and (ii) any sale of the shares of Common Stock made in reliance on Rule 144 may be made only in accordance with
the terms of Rule 144.

 

4.
COVENANTS.

 

4.1
Reasonable Best Efforts. The Company shall use its reasonable best efforts to timely satisfy each of the conditions
to be satisfied by it as provided in Section 6 of this Agreement. The Securityholder shall use its reasonable best efforts to
timely satisfy each of the conditions to be satisfied by it as provided in Section 5 of this Agreement.

 

5.
CONDITIONS TO COMPANY’S OBLIGATIONS HEREUNDER.

 

The
obligations of the Company to the Securityholder hereunder are subject to the satisfaction of each of the following conditions
(except to the extent such condition is expressly conditional to a specific closing, in which case such condition shall only apply
to such specific closing), provided that these conditions are for the Company’s sole benefit and may be waived by the Company
at any time in its sole discretion by providing the Securityholder with prior written notice thereof:

 

5.1 The Securityholder
shall have duly executed this Agreement and delivered the same to the Company and shall have delivered the certificates evidencing
the Series B Preferred (or, in the event of the loss, theft or destruction of the Series B Preferred stock certificate, an affidavit
with respect thereto in form reasonably acceptable to the Company).

 

5.2
The representations and warranties of the Securityholder shall be true and correct in all material respects as of the date
when made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a
specific date which shall be true and correct as of such specified date), and the Securityholder shall have performed, satisfied
and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed,
satisfied or complied with by the Securityholder at or prior to the Closing Date.

 

5.3No
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated
by this Agreement.

 

5.4The
Private Placement shall have been consummated.

 

    	6

    	 

    

 

6.
CONDITIONS TO THE SECURITYHOLDER’S OBLIGATIONS HEREUNDER.

 

The
obligations of the Securityholder hereunder are subject to the satisfaction of each of the following conditions (except to the
extent such condition is expressly conditional to a specific closing, in which case such condition shall only apply to such specific
closing), provided that these conditions are for the Securityholder’s sole benefit and may be waived by the Securityholder
at any time in its sole discretion by providing the Company with prior written notice thereof:

 

6.1The
Company shall have duly executed and delivered this Agreement to the Securityholder.

 

6.2Each
and every representation and warranty of the Company shall be true and correct in all material respects as of the date when made
and as of the Closing Date as though originally made at that time (except for representations and warranties that speak as of
a specific date, which shall be true and correct as of such date) and the Company shall have performed, satisfied and complied
in all material respects with the covenants, agreements and conditions required to be performed, satisfied or complied with by
the Company at or prior to the Closing Date.

 

6.3
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for
the transactions contemplated by this Agreement.

 

6.4
No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by this Agreement.

 

6.5The
Private Placement Closing Date shall have occurred.

 

7. MISCELLANEOUS.

 

7.1 Legends.
The Securityholder acknowledges that the certificate(s) representing the shares of Common Stock shall conspicuously set forth
on the face or back thereof a legend in substantially the following form:

 

“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE RULES AND REGULATIONS
PROMULGATED THEREUNDER, OR UNDER THE SECURITIES LAWS, RULES OR REGULATIONS OF ANY STATE; AND MAY NOT BE PLEDGED, HYPOTHECATED,
SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE ACT AND THE APPLICABLE
STATE SECURITIES LAWS, RULES OR REGULATIONS OR AN EXEMPTION THEREFROM DEEMED ACCEPTABLE BY COUNSEL TO THE COMPANY.”

 

7.2
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law
or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of New York.

 

    	7

    	 

    

 

7.3Arbitration.
Both parties shall resolve all disputes, controversies and differences which may arise between the parties, out of or in relation
to or in connection with this Agreement, after discussion in good faith attempting to reach an amicable solution. Provided that
such disputes, controversies and differences remain unsettled after discussion between the parties, both parties agree that those
unsettled matter(s) shall be finally settled by arbitration in New York, New York in accordance with the latest Rules of the American
Arbitration Association. Such arbitration shall be conducted by three arbitrators appointed as follows: each party will appoint
one arbitrator and the appointed arbitrators shall appoint a third arbitrator. If within 30 days after confirmation of the last
appointed arbitrator, such arbitrators have failed to agree upon a chairman, then the chairman will be appointed by the American
Arbitration Association. The decision of the tribunal shall be final and may not be appealed. The arbitral tribunal may, in its
discretion award fees and costs as part of its award. Judgment on the arbitral award may be entered by any court of competent
jurisdiction, including any court that has jurisdiction over either party or any of their assets. At the request of any party,
the arbitration proceeding shall be conducted in the utmost secrecy subject to a requirement of law to disclose. In such case,
all documents, testimony and records shall be received, heard and maintained by the arbitrators in secrecy, available for inspection
only by any party and by their attorneys and experts who shall agree, in advance and in writing, to receive all such information
in secrecy.

 

7.4
Counterparts. This Agreement may be executed simultaneously in two or more counterparts, any one of which need not
contain the signatures of more than one party, but all such counterparts taken together will constitute one and the same Agreement.
This Agreement, to the extent delivered by means of a facsimile machine or electronic mail (any such delivery, an “Electronic
Delivery”), shall be treated in all manner and respects as an original agreement or instrument and shall be considered
to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of
any party hereto, each other party hereto shall re-execute original forms hereof and deliver them in person to all other parties.
No party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement
or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract,
and each such party forever waives any such defense, except to the extent such defense related to lack of authenticity.

 

7.5
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement.

 

7.6Severability.
If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without
material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity
or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will
endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s),
the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

    	8

    	 

    

 

7.7
Entire Agreement; Amendments. This Agreement supersedes all other prior oral or written agreements between the Securityholder,
the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement,
contains the entire understanding of the parties with respect to the matters covered herein and, except as specifically set forth
herein, neither the Company nor the Securityholder makes any representation, warranty, covenant or undertaking with respect to
such matters. No provision of this Agreement may be amended other than by an instrument in writing signed by the Company and the
Securityholder, and any amendment to this Agreement made in conformity with the provisions of this Section shall be binding upon
the Securityholder. No provision hereof may be waived other than by an instrument in writing signed by the party against whom
enforcement is sought.

 

7.8Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when
sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); or (iii) one business day after deposit with an overnight courier service, in each case properly addressed to the party
to receive the same. The addresses and facsimile numbers for such communications shall be:

 

If to the
Company:

 

XRpro Sciences, Inc.

One Kendall Square

Cambridge, Massachusetts 02139

Attention: Richard Cunningham

 

 

with a copy
(for informational purposes only) to:

 

Gracin &
Marlow, LLP

The Chrysler
Building

405 Lexington
Avenue, 26th Floor

New York,
New York 10174

Telephone:
(212) 907-6457

Facsimile:
(212) 208-4657

Attention:
Leslie Marlow, Esq.

 

If to the
Securityholder:

 

 

 

with a copy
(for informational purposes only) to:

 

 

 

to
its address and facsimile number set forth above, or to such other address and/or facsimile number and/or to the attention of
such other person as the recipient party has specified by written notice given to each other party five days prior to the effectiveness
of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication;
(B) mechanically or electronically generated by the sender's facsimile machine containing the time, date, recipient facsimile
number and an image of the first page of such transmission; or (C) provided by an overnight courier service shall be rebuttable
evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i),
(ii) or (iii) above, respectively.

 

    	9

    	 

    

 

7.9
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and assigns, including any purchasers of the Series B Preferred. The Company shall not assign this Agreement or any
rights or obligations hereunder without the prior written consent of the Securityholder. The Securityholder may assign some or
all of its rights hereunder without the consent of the Company.

 

7.10Construction.
The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and
no rules of strict construction will be applied against any party. No specific representation or warranty shall limit the generality
or applicability of a more general representation or warranty.

 

    	10

    	 

    

 

IN
WITNESS WHEREOF, the Securityholder and the Company have caused their respective signature pages to this Agreement to be duly
executed as of the date first written above.

 

	 	COMPANY:
	 	 
	 	XRPRO SCIENCES, INC. 
	 	 	 
	 	By:	 
	 	Name: 	Richard Cunningham
	 	Title:	President and Chief Executive Officer

 

	 	SECURITYHOLDER:
	 	 
	 	 
	 	Print Name
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name and Title of Signer
	 	 
	 	 
	 	Name (if Joint)
	 	 
	 	 
	 	Signature (if Joint)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]